Pharmaceutical UK-based Abcam (AIM: ABC), a producer and distributor of protein research tools, has entered into a license agreement with global pharma behemoth Pfizer (NYSE: PFE). Under the terms of the agreement, Abcam's Biochemicals division will supply a range of authentic Pfizer compounds for use as preclinical research tools by researchers worldwide, alongside the Abcam Biochemicals range of over 2000 bioactive small molecules. 12 June 2013